As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The HEALION Division of Hetero Healthcare is focused on providing therapeutic solutions across pain management, inflammation, musculoskeletal health, and bone and joint care. The division addresses conditions that can affect mobility, physical comfort, and everyday functioning, with a portfolio designed to support healthcare professionals in managing both acute and chronic musculoskeletal concerns.
Its therapeutic portfolio encompasses key areas such as pain and inflammation management, osteoarthritis and joint-related conditions, muscle pain and spasms, bone health, and nutritional support for musculoskeletal well-being. Through targeted therapeutic and supportive approaches, HEALION aims to address diverse orthopaedic and musculoskeletal healthcare needs while supporting mobility, recovery, and overall quality of life.
Backed by Hetero Healthcare’s commitment to quality, accessibility, innovation, and patient-centric care, the HEALION Division strives to provide dependable therapeutic options that complement effective clinical management. With its focused approach to pain, bone, joint, and musculoskeletal health, HEALION continues to support healthcare professionals in addressing evolving patient needs and contributing to better treatment outcomes.
View by-
